Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Retinoic Acid Receptor Gamma Pipeline Drugs Market Report Overview
Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG binds as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulates the gene expression in various biological processes. The Retinoic Acid Receptor Gamma pipeline drugs market research report outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule types that are being developed by companies/universities. Furthermore, it also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects.
RAR Gamma Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas in the RAR Gamma pipeline drugs market are dermatology, musculoskeletal disorders, ophthalmology, respiratory, gastrointestinal, immunology, infectious disease, metabolic disorders, and oncology.In 2022, dermatology is the leading therapy area in the RAR Gamma pipeline drugs market.
RAR Gamma Pipeline Drugs Market Analysis by Therapy Areas, 2022 (%)
For more therapy area insights into the RAR Gamma pipeline drugs market, download a free report sample
RAR Gamma Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of actions in the RAR Gamma pipeline drugs market are Retinoic Acid Receptor Gamma Agonist and Retinoic Acid Receptor Gamma Antagonist.In 2022, Retinoic Acid Receptor Gamma Agonist was the leading mechanism of action in the RAR Gamma pipeline drugs market.
RAR Gamma Pipeline Drugs Market Analysis by Mechanism of Actions, 2022 (%)
For more mechanism of action insights into the RAR Gamma pipeline drugs market, download a free report sample
RAR Gamma Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the RAR Gamma pipeline drugs market are topical, oral, ophthalmic, cutaneous, and inhalational. In 2022, most of the drugs were administered through the topical route.
RAR Gamma Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)
For more routes of administration insights into the RAR Gamma pipeline drugs market, download a free report sample
RAR Gamma Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the RAR Gamma pipeline drugs market are small molecule and protein. In 2022, small molecule was the leading molecule type in the RAR Gamma pipeline drugs market.
RAR Gamma Pipeline Drugs Market by Molecule Types, 2022 (%)
For more molecule type insights into the RAR Gamma pipeline drugs market, download a free report sample
RAR Gamma Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the RAR Gamma pipeline drugs market are Advent Therapeutics Inc, Avecho Biotechnology Ltd, Bausch Health Companies Inc, Boehringer Ingelheim International GmbH, Galephar Pharmaceutical Research Inc, Ipsen SA, Lee’s Pharmaceutical Holdings Ltd, Orphanix GmbH, Ortho Dermatologics Inc, and Promius Pharma LLC. In 2022, Ipsen SA dominated the RAR Gamma pipeline drugs market.
RAR Gamma Pipeline Drugs Market Analysis by Companies, 2022 (%)
To know more about the leading companies of the RAR Gamma pipeline drugs market, download a free report sample
Retinoic Acid Receptor Gamma Pipeline Drugs Market Report Overview
| Key Therapy Areas | Dermatology, Musculoskeletal Disorders, Ophthalmology, Respiratory, Gastrointestinal, Immunology, Infectious Disease, Metabolic Disorders, and Oncology |
| Key Mechanism of Actions | Retinoic Acid Receptor Gamma Agonist and Retinoic Acid Receptor Gamma Antagonist |
| Key Routes of Administration | Topical, Oral, Ophthalmic, Cutaneous, and Inhalational |
| Key Molecule Types | Small Molecule and Protein |
| Key Companies | Advent Therapeutics Inc, Avecho Biotechnology Ltd, Bausch Health Companies Inc, Boehringer Ingelheim International GmbH, Galephar Pharmaceutical Research Inc, Ipsen SA, Lee’s Pharmaceutical Holdings Ltd, Orphanix GmbH, Ortho Dermatologics Inc, and Promius Pharma LLC |
Segments Covered in the Report
RAR Gamma Pipeline Drugs Market Therapy Areas Outlook
- Dermatology
- Musculoskeletal Disorders
- Ophthalmology
- Respiratory
- Gastrointestinal
- Immunology
- Infectious Disease
- Metabolic Disorders
- Oncology
RAR Gamma Pipeline Drugs Market Mechanism of Actions Outlook
- Retinoic Acid Receptor Gamma Agonist
- Retinoic Acid Receptor Gamma Antagonist
RAR Gamma Pipeline Drugs Market Routes of Administration Outlook
- Topical
- Oral
- Ophthalmic
- Cutaneous
- Inhalational
RAR Gamma Pipeline Drugs Market Molecule Types Outlook
- Small Molecule
- Protein
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG).
- Reviews of Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects.
- Assessment of Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summarization of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Avecho Biotechnology Ltd
Bausch Health Companies Inc
Boehringer Ingelheim International GmbH
Galephar Pharmaceutical Research Inc
Ipsen SA
Lee's Pharmaceutical Holdings Ltd
Orphanix GmbH
Ortho Dermatologics Inc
Promius Pharma LLC
Sveikatal Inc
TherapyX Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the RAR Gamma pipeline drugs market?
Some of the key therapy areas in the RAR Gamma pipeline drugs market are dermatology, musculoskeletal disorders, ophthalmology, respiratory, gastrointestinal, immunology, infectious disease, metabolic disorders, and oncology.
-
What are the key mechanism of actions in the RAR Gamma pipeline drugs market?
The key mechanism of actions in the RAR Gamma pipeline drugs market are Retinoic Acid Receptor Gamma Agonist and Retinoic Acid Receptor Gamma Antagonist.
-
What are the key routes of administration in the RAR Gamma pipeline drugs market?
The routes of administration in the RAR Gamma pipeline drugs market are topical, oral, ophthalmic, cutaneous, and inhalational.
-
What are the key molecule types in the RAR Gamma pipeline drugs market?
The key molecule types in the RAR Gamma pipeline drugs market are small molecule and protein.
-
Which are the key companies in the RAR Gamma pipeline drugs market?
The key companies in the RAR Gamma pipeline drugs market are Advent Therapeutics Inc, Avecho Biotechnology Ltd, Bausch Health Companies Inc, Boehringer Ingelheim International GmbH, Galephar Pharmaceutical Research Inc, Ipsen SA, Lee’s Pharmaceutical Holdings Ltd, Orphanix GmbH, Ortho Dermatologics Inc, and Promius Pharma LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports